Riskpilot← Back to searchSign inGet full accessCell to Cure ApS
APSActiveCVR 39401975Kajerødgård 9Research and experimental development on natural sciences and engineering · NACE 7210Est. 201814 employees
Revenue 2024
DKK -2,8M
-2893% vs 2023
EBITDA margin
327.8%
-404% vs 2023
Equity ratio
51.2%
Financial strength
Net profit 2024
DKK -7M
-356% vs 2023
| Revenue | DKK -2,8M | -2893% |
| EBITDA | DKK -9,2M | -404% |
| Net profit | DKK -7M | -356% |
| Total assets | DKK 6,1M | +225% |
| Equity | DKK 3,1M | +264% |
| Employees | 14 | — |
Legal name
Cell to Cure ApS
CVR number
39401975
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
7. marts 2018
Share capital
DKK 120.288
Employees
14 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse i forening eller af bestyrelsesformanden i forening med enten ét andet bestyrelsesmedlem eller én direktør
Company purpose
Selskabets formål er at drive virksomhed med handel, rådgivning og assistance inden for farmaceutisk og bioteknologisk industri og beslægtede brancher, samt anden dermed beslægtet virksomhed.
Address
Kajerødgård 9
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -9 | 523 | 295 | 389 | 100 | -2.803 |
| Staff expenses | -0 | -0 | -0 | -1.047 | -1.922 | -6.385 |
| EBITDA | -9 | 523 | 295 | -658 | -1.821 | -9.187 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -9 | 523 | 295 | -658 | -1.821 | -9.187 |
| Net financials | -13 | -6 | -15 | -14 | -110 | -52 |
| Profit before tax | -23 | 517 | 280 | -672 | -1.931 | -9.240 |
| Tax | -0 | 112 | 62 | -270 | -398 | -2.253 |
| Net profit | -23 | 405 | 218 | -402 | -1.534 | -6.987 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 309 | 839 | 1.014 | 1.487 | 1.871 | 6.080 |
| Equity | 43 | 462 | 695 | -366 | -1.899 | 3.114 |
| Long-term debt | 0 | 112 | 62 | 0 | 1.392 | 0 |
| Short-term debt | 266 | 266 | 258 | 1.853 | 2.353 | 2.966 |
| Total debt | 266 | 377 | 320 | 1.853 | 3.746 | 2.966 |
EBITDA margin
-918745000.0%
This company
15.8%
Market median
-5814841872% vs market
20192024
Equity ratio
51.2%
This company
38.2%
Market median
+34% vs market
20192024
Return on equity
-224.4%
This company
18.4%
Market median
-1320% vs market
20192024
Net profit margin
-698712800.0%
This company
8.1%
Market median
-8626084051% vs market
20192024
Asset turnover
-0.46×
This company
1.12×
Market median
-141% vs market
20192024
Debt / equity
0.95×
This company
0.62×
Market median
+53% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2023-09-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via CVR / Virk · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via CVR / Virk · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via CVR / Virk · Period 2019-09-01 – 2020-08-31
- Annual report 2019Filed via CVR / Virk · Period 2018-03-07 – 2019-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MR Management | Management | 2022 | — | — |
MH Management | Management | 2018 | — | — |
JK Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
AE Management | Management | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Endeavour Cells ApS | Company | 50.0% | 50.0% | 2024 |
JKastrup.ApS | Company | 10.0% | 10.0% | 2024 |
Ekblond.ApS | Company | 10.0% | 10.0% | 2024 |
LMN.ApS | Company | 10.0% | 10.0% | 2024 |
MEDIC ADVICE ApS | Company | 5.0% | 5.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MEDIC ADVICE ApS
Cell to Cure ApS Board members of Cell to Cure ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Roland Jensen | Management | 0 companies |
| Mandana Haack-Sørensen | Management | 0 companies |
| Jens Kastrup | Chief Executive Officer | 0 companies |
| Annette Ekblond | Management | 0 companies |
| Jesper Kihl | Board of Directors | 0 companies |
| Anders Østergaard | Chairman | 0 companies |